Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].
Pancreatitis occurs in up to 7% of patients infected with human immunodeficiency virus who are treated with standard doses of didanosine. Tenofovir disoproxil fumarate increases the plasma levels of didanosine and, thus, the combination of these agents may increase the risk of pancreatitis. Four cases of pancreatitis that occurred during administration of this drug combination are examined, including 1 that resulted in death.
Blanchard
Jennifer N
JN
Division of General Internal Medicine, University of California, San Diego Medical Center, 92103-8681, USA. jblanchard@ucsd.edu
Wohlfeiler
Michael
M
Canas
Albert
A
King
Kevin
K
Lonergan
J Tyler
JT
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000328:Adult; D016049:Didanosine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D004347:Drug Interactions; D017809:Fatal Outcome; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010195:Pancreatitis / Q000139:chemically induced / Q000188:drug therapy*; D000068698:Tenofovir
D063065:Organophosphonates; D009943:Organophosphorus Compounds; D000068698:Tenofovir; D000225:Adenine; D016049:Didanosine